Isn’t it wonderful how our company puts out these little...

Isn’t it wonderful how our company puts out these little understatements hidden away in shareholder updates which could have momentous repercussions in the over the counter pharmaceutical industry!!!!


GSK ANALGESIC PROGRAM

The Company is pleased to advise the SUCCESSFUL completion of the Phase II Analgesic program with GSK Pharmaceuticals announced in December




A New Consumer Health Powerhouse: GSK and Novartis to Form a Joint Venture –

See more at: http://blog.euromonitor.com/2014/04/a-new-consumer-health-
powerhouse-gsk-and-novartis-to-form-a-joint-venture.html#sthash.cYA6KczU.dpuf


A key driver for the merger was the complementary nature of the product portfolios. Together, GSK and Novartis have over 24 brands with annual sales of US$100 million, and another 12 with sales of US$50 million or more.

As these companies are mostly focused in OTC, the top selling categories will be

ANALGESICS led by GSK’s Panadol and Novartis’s Voltaren,

and cough, cold, and allergy (hayfever) remedies (CCA), led by Novartis’s Otrivin and Theraflu and GSK’s Coldrex. The new partnership should boost the venture to the leadership position in each of these highly competitive markets. It will also be a powerhouse in digestive remedies, dermatologicals, and NRT smoking cessation aids, as well as in the smaller scale categories eye care and adult mouth care. - See more at: http://blog.euromonitor.com/2014/04/a-new-consumer-health-powerhouse-gsk-and-novartis-to-form-a-joint-venture.html#sthash.cYA6KczU.dpuf